in the news
June 12, 2023
Data shows a new blood test provides information linked to the likelihood of anaphylaxis in peanut allergic individuals.
June 7, 2023
llerGenis Announces Presentations at EAACI Congress 2023: Pathways From Precision Medicine to Personalized Health Care
December 29, 2022
CEO will present progress throughout 2022 and outlook for 2023. Allergenis, a commercial stage biotechnology company which aims to revolutionize the diagnosis and management of food allergy, today announced it is presenting at the upcoming Biotech Showcase™ 2023 conference, coinciding with the 41st Annual J.P. Morgan Health Care Conference in San Francisco, January 9-12, 2023.
December 29, 2022
CEO will present progress throughout 2022 and outlook for 2023. Allergenis, a commercial stage biotechnology company which aims to revolutionize the diagnosis and management of food allergy, today announced it is presenting at the upcoming Biotech Showcase™ 2023 conference, coinciding with the 41st Annual J.P. Morgan Health Care Conference in San Francisco, January 9-12, 2023.
Americans are now more concerned about their mental health than Covid, according to a recent poll from Ipsos.
The U.S. Preventive Services Task Force, which advises the Health and Human Services Department, recommended anxiety screening for children and teenagers this month. It is taking public comment through Oct. 17 on a draft recommendation that all adults be evaluated, too.
The situation is motivating lawmakers in both parties to provide an increasingly stressed, depressed and anxious populace with the appropriate care.
Epitope testing has been shown in studies to be far more reliable in diagnosing peanut allergy than traditional skin or blood testing. Now, new research reveals that epitope testing is also good at determining if a child with peanut allergy will react to trace amounts, or if they can consume one or more peanuts before starting to react.
The epitope test is the first to provide reaction “thresholds.” These may be useful for families in deciding how careful they need to be in avoiding peanuts. This includes whether their child can safely eat foods with the “may contain” warning.
Allergenis’ bead-based epitope assay at center of study from Mount Sinai revealing breakthrough diagnostic for peanut allergy
As a toddler, Colton McClure never wanted to eat peanut butter. "He would always push it away," said his mom, Cheri McClure.
Then when he was a preschooler, Colton ate one Reese's peanut butter cup and was fine. After the second one, he threw up. "Something is not right," McClure said.
An allergy skin prick test produced a reaction to peanuts, tree nuts and shellfish.
The McClures, who live in Austin, immediately changed what they did. They wouldn't go to restaurants, for fear of cross-contamination. They looked at shampoos and soaps to make sure nothing Colton was allergic to was in them. They looked at processed foods for all his allergens and avoided them. They even called companies to ask what their protocols were at their manufacturing plants.
Predictive analytics company Allergenis, which specializes in the detection and management of life-threatening food allergies, announced today a breakthrough diagnostic tool for the detection and management of peanut allergy developed with researchers at the Icahn School of Medicine at Mount Sinai. The bead-based epitope assay (BBEA) looks at select epitopes known to cause patient reactivity to accurately identify the cumulative tolerated dose of patients to inform clinical management of peanut allergy.
Allergenis’ bead-based epitope assay at center of study from Mount Sinai revealing breakthrough diagnostic for peanut allergy
Allergenis today announced the results of extensive research and development of a novel diagnostic tool. A peer-reviewed journal article detailed this breakthrough advancement in the diagnosis and management of peanut allergy. The validated results can be found in a recent article, published in Allergy. Years of research and validation, conducted at the Icahn School of Medicine at Mount Sinai in New York (Icahn Mount Sinai) with Allergenis, included breaking down peanut proteins to look at select epitopes which cause reactivity in patients. Using bead-based epitope assay (BBEA), researchers were able to accurately identify the cumulative tolerated dose of patients to inform clinical management of peanut allergy. Allergenis holds the exclusive license to this technology from Mount Sinai…
Telehealth firm LifeMD said this week that its wholly owned subsidiary Cleared is partnering with Allergenis to offer that firm's peanut allergy diagnostic blood test. Cleared will be the exclusive telehealth provider for the commercial launch of the test. The laboratory-developed test provides patients their reactivity level to peanuts and is validated for individuals ages 4 and above.
Traditional allergy tests are often inaccurate, leading to overdiagnosis, and don’t offer much insight into the amount of an allergen a person can safely consume.
That could mean living in fear when you don’t need to. Pennsylvania startup Allergenis is trying to change that with a new type of blood test that can help patients know how much of an allergen they can tolerate.
Skin and blood tests to diagnose peanut allergy are known to have a high rate of false positives – as much as 50 percent. This leads to many people being wrongly diagnosed as allergic, and to a life of strict peanut avoidance.
A new test, using a technique called epitope mapping, does better – it diagnoses peanut allergy correctly over 90 percent of the time. Also helpful: the epitope test appears to determine how much peanut an allergic individual can tolerate without reacting.
August 2022
Maria Suprun, Paul Kearney, Clive Hayward, Heather Butler, Robert Getts, Scott H. Sicherer, Paul J. Turner, Dianne E. Campbell, Hugh A. Sampson
July 2022
Maria Suprun, Paul Kearney, Clive Hayward, Heather Butler, Robert Getts, Scott H. Sicherer, Paul Turner, Dianne E. Campbell, Hugh A. Sampson
June 2022
Sayantani B. Sindher, Andrew Long, Andrew R. Chin, Angela Hy, Vanitha Sampath, Kari C. Nadeau, R. Sharon Chinthrajah
November 2021
Suprun M., Sicherer S.H., Wood R.A., Jones S.M., Leung D.Y.M., Burks A.W., Dunkin D., Witmer M., Grishina G., Getts R., Suárez-Fariñas M., Sampson H.A.
Int Arch Allergy Immunol 2022;183:249–261
AllerGenis announced the publication of a peer-reviewed study entitled, "Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping." Conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, Stanford University and Kings College, the study found the AllerGenis peanut diagnostic blood test demonstrates accuracy significantly and statistically superior to all other established diagnostic tests. The AllerGenis peanut allergy diagnostic, which relies on analyzing a small amount of blood, resulted in 93% accuracy rate as compared to an oral food challenge without the risk of triggering an allergic reaction. The study is published in the prestigious global impact journal Allergy, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI).
The findings are life-changing for food allergy patients who previously turned to a potentially risky and often anxiety-producing procedure called an oral food challenge (OFC) to rule out a food allergy.
A blood test called “epitope mapping” accurately predicted peanut allergy 93 percent of the time, a recent study finds. Researchers say the new test is a significant improvement on existing tests for diagnosing peanut allergy, including skin prick tests and allergen-specific IgE blood tests. Those current tests can be unreliable in determining who will actually experience an allergic reaction to peanuts.
Beyond diagnosing peanut allergy, Sampson envisions other uses for epitope mapping. He and his colleagues are gathering data showing that epitope mapping may be able to determine roughly how much peanut someone could consume without reacting.
Chief Science Officer and head of product and clinical development to present advancements in food allergy diagnostics highlighting the company's new peanut allergy sensitivity assay
AllerGenis today announced that the company's chief scientific officer and head of product and clinical development, Paul Kearney, PhD, will be speaking at the Institute for the Advancement of Food and Nutrition Science (IAFNS) Annual meeting on a panel entitled, "New Innovations in Food Allergy Testing and Patient Care.”
"I look forward to sharing how AllerGenis is shaping the future of food allergy diagnostics and the several advancements we're working hard to bring to patients and caregivers across the country," said Dr. Kearney. "This includes our newest innovation – a peanut sensitivity assay – that can determine the amount of peanut protein likely to cause an allergic reaction when ingested which may also be used when assessing the progression of peanut allergy desensitization. This advancement can positively impact the lives of millions of patients and caregivers who are navigating the complexities of life with a food allergy while also providing an easier way to safely navigate food labeling."
June 2021
Mayte Suárez-Fariñas, Maria Suprun, Paul Kearney, Robert Getts, Galina Grishina, Clive Hayward, David Luta, Alex Porter, Marc Witmer, George du Toit, Gideon Lack, Rebecca Sharon Chinthrajah, Stephen J. Galli, Kari Nadeau, Hugh A. Sampson
According to a recent McKinsey report, more than 30 million people (5.6 million are children) in the U.S. have been diagnosed with food allergies. Their families are impacted as well, resulting in nearly 85 million Americans changing the way they eat at home and in restaurants.
Seeing this as an opportunity, and focused on the fact that the over-diagnosis rate for food allergies is more than 60 percent, biotech company AllerGenis, founded in 2017, developed a precision diagnostic platform that utilizes current state-of-the-art technology that is significantly more accurate, guiding them in their mission to ensure that food allergy sufferers are better informed around the need for making safe food choices and attaining an improved quality of life.
AllerGenis LLC today announced that CEO Jim Garner will be speaking at the Biotech Showcase™ 2021. Mr. Garner's presentation will showcase the significant achievements AllerGenis has reached in its mission to develop precision diagnostic solutions that help healthcare providers better assess and manage the well-being of millions of food allergy patients.
Most notably, AllerGenis has commercially launched the first product in its pipeline, VeriMAP™ Peanut Diagnostic. With a 95% positive predictive value, VeriMAP can help reduce overdiagnosis and anxiety by minimizing false positives. As many as 60% of food allergy sufferers may be misdiagnosed, leading to unnecessary food avoidance, increased patient anxiety, and annual costs of nearly $25 billion in the US alone.
AllerGenis LLC today announced that positive new data about an innovative approach to track the progress of peanut allergy desensitization utilizing AllerGenis' Epitope Mapping Platform in children undergoing epicutaneous immunotherapy for peanut allergy (DBV712 250 µg) being developed by DBV Technologies, will be presented at the American College of Allergy and Asthma & Immunology (ACAAI) virtual 2020 Annual Scientific Meeting. The presentation, a partnership with DBV Technologies, is titled, "Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy," and will be given by David Fleischer, MD, Professor of Pediatrics and Section Head, Children's Hospital Colorado, at 3:33 p.m. CST on Saturday, November 14. Access full abstract here.
The results to be presented at ACAAI are based on samples from subjects who participated in the Efficacy and Safety of Viaskin Peanut in Children with Immunoglobulin E (IgE)-Mediated Peanut Allergy (PEPITES) study (NCT02636699). This was a Phase 3, double-blind, randomized controlled trial of children aged four to 11 years with peanut allergies who were treated with DBV712 250 µg or placebo for 12 months. Daily treatment with investigational DBV712 250 µg (approximately 1/1000 one peanut) was shown to result in a statistically significant increase in desensitization in peanut-allergic children aged four to 11 years compared with placebo.
November 2020
Maria Suprun, Robert Getts, Galina Grishina, Angela Tsuang, Mayte Suárez-Fariñas, Hugh A. Sampson
Allergy. 2020;75:2633–2643.
August 2020
Maria Suprun MPH, Scott H. Sicherer MD, Robert A. Wood,MD, Stacie M. Jones MD, Donald Y. M. Leung MD, PhD, Alice K. Henning MS, Peter Dawson PhD, A. Wesley Burks MD, Robert Lindblad MD, Robert Getts PhD, Mayte Suarez-Fari~nas PhD, and Hugh A. Sampson MD
J Allergy Clin Immunol 2020;146:1080-8.
AllerGenis LLC today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAPTM Peanut Diagnostic, a diagnostic solution for patients with peanut allergies. AllerGenis received full certification under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform its high complexity clinical laboratory testing. This is a crucial step for the company as it begins offering VeriMAP Peanut Diagnostic to Centers of Excellence and community allergists over the next few months, with plans to expand into additional allergy centers in early 2021.
"It has been decades since the last technological breakthrough in food allergy diagnosis," says Jim Garner, CEO of AllerGenis.
Company to present validation data of its VeriMAPTM Peanut Diagnostic and showcase the broad application of its next-generation food allergy diagnostic platform to assess response to immunotherapy
Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtually from June 6th through 8th. AllerGenis will have two presentations at the Congress, which are include:
Thematic Poster Presentation: Repeated validation of a high-performing peanut allergy diagnostic on POISED trial subjects
Presenter: Paul Kearney, Head of Product and Clinical Development, AllerGenis; andLate Breaking Oral Abstract Presentation: Differences in epitome response in peanut-allergic subjects treated with different immunotherapy preparations
Presenter: Dianne Campbell, VP, Scientific and Medical Affairs, Australia and New Zealand, DBV Technologies
Both presentations will be available to conference registrants from EAACI’s website up to six months after the event.
AllerGenis CEO Jim Garner joined Proactive at the Biotech Showcase 2020 in San Francisco.
AllerGenis CEO Jim Garner joined Proactive at the Biotech Showcase 2020 in San Francisco. The privately-held, Pennsylvania-based company develops data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies.
AllerGenis today announced that CEO Jim Garner will be presenting during the Biotech Showcase at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Mr. Garner’s presentation will highlight the upcoming 2020 introduction of AllerGenis’ food allergy diagnostic platform, which more than triples diagnostic precision compared to current food allergy testing.
The presentation, titled, “Revolutionizing the Diagnosis and Management of Food Allergy,” can be webcast live (Link), and will be available for streaming on the “Resources” section of the company’s website, www.allergenis.com, following the presentation.